PRISM MarketView
    Biodexa Pharmaceuticals Reports 12-Month Survival in Glioblastoma Patients
    New York, February 09, 2024 - PRISM MarketView - Biodexa Pharmaceuticals (Nasdaq: BDRX) has provided survival updates from its clinical study of MTX110 in patients with recurrent glioblastoma (“rGBM”). Currently, no standard of care is established for rGBM.

    9 February 2024

    read more...
    PRISM MarketView
    AIM ImmunoTech Tackles Post-COVID Fatigue
    New York, February 09, 2024 - PRISM MarketView -  AIM ImmunoTech (NYSE American: AIM) has reported positive topline results from a Phase 2 study evaluating the efficacy and safety of Ampligen® as a potential therapeutic for people with the Post-COVID condition of fatigue...

    9 February 2024

    read more...
    PRISM MarketView
    Cronos Group’s Spinach® Brand Cannabis Takes Top Spot in Canada
    New York, February 08, 2024 - PRISM MediaWire - Innovative global cannabinoid company, Cronos Group’s (Nasdaq: CRON), Spinach brand has emerged as the top contender in Canada’s burgeoning cannabis market, securing the coveted position of the number one flower brand in th...

    8 February 2024

    read more...
    PRISM MarketView
    GrowGeneration Celebrates Drip Hydro’s Innovative Nutrient Line for Cannabis Cultivation
    New York, February 08, 2024 - PRISM MediaWire  - Drip Hydro has shaken up the cannabis cultivation industry with the introduction of its innovative powder nutrient line, designed specifically to optimize plant health and crop quality. This game-changing product marks a s...

    8 February 2024

    read more...
    PRISM MarketView
    Microbot Medical Takes Step Towards Human Clinical Trial in US
    New York, February 08, 2024 - PRISM MediaWire - Surgical robotics company, Microbot Medical (Nasdaq: MBOT) has taken an important step closer to initiating a pivotal human clinical trial in the United States with the filing of an Investigational Device Exemption (IDE) ap...

    8 February 2024

    read more...
    PRISM MarketView
    John Madden’s “BOOM-Worthy” Stock Picks and Playbook for Blitzing Sunday’s Super Bowl Party
    New York, February 07, 2024 - PRISM MediaWire - PRISM MarketView - On Sunday night, Super Bowl LVIII will be taking place in Las Vegas as the Kansas City Chiefs match up against the San Francisco 49ers. While this match up doesn’t seem to excite most anyone in the other ...

    7 February 2024

    read more...
    PRISM MarketView
    Biotech Breakfast – Healthcare Equities Outperform; Alto Neuroscience and Fractyl Health IPO; Tyra Biosciences, ImmunityBio Surge
    New York, February 05, 2024 - PRISM MarketView - Healthcare equities outperformed last week with Managed Care a standout. The S&P 500 Healthcare Index gained +1.98% versus the S&P 500 Index which was up +1.38%. The week was more difficult for Biotech, MedTech, Se...

    5 February 2024

    read more...
    PRISM MarketView
    Are We Investing Enough in Vaccine Development?
    New York, February 02, 2024 - PRISM MarketView - Vaccination is one of the top 10 most significant public health achievements of the 20th century and remains the most effective preventive measure against infectious diseases. Diseases such as smallpox and polio, which can...

    3 February 2024

    read more...
    PRISM MarketView
    PRISM MarketView Marks World Cancer Day
    New York, February 01, 2024 - PRISM MediaWire - PRISM MarketView, a leading provider of unbiased market insight and company news, today recognizes the tremendous contributions of companies striving to develop treatments for cancer, a complex disease driven by numerous fa...

    1 February 2024

    read more...
    Medical Devices
    SS Innovations Demonstrates Groundbreaking Telesurgery Platform at Company’s First Multi-Specialty Robotic Surgical Conference
    Remote coronary artery suturing performed on animal model via SS Innovations’ telesurgery platform

    1 February 2024

    read more...
    15
    16
    17
    18
    19
    20
    21
    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.